Начало › Хронична лимфоцитна левкемия › Вашингтон › Seattle
Клинични проучвания за Хронична лимфоцитна левкемия в Seattle, WA
20 проучвания за Хронична лимфоцитна левкемия търсят участници в обекти в и около Seattle (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- и още 1
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Набиране на участнициФаза 1/2
- Research Site, Seattle
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Набиране на участнициФаза 3
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- и още 1
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Набиране на участнициФаза 3
- Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Набиране на участнициФаза 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Набиране на участнициФаза 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Набиране на участнициФаза 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Набиране на участнициФаза 3
- Fred Hutchinson Cancer Research Center, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набиране на участнициФаза 3
- Fred Hutchinson Cancer Research Center, Seattle
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Набиране на участнициФаза 2
- Fred Hutchinson Cancer Center, Seattle
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Набиране на участнициФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Набиране на участнициФаза 1
- Fred Hutch Cancer Center, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Набиране на участнициФаза 2Здравите доброволци са добре дошли
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Набиране на участнициФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Набиране на участнициФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Набиране на участнициФаза 4
- Swedish Cancer Institute, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Набиране на участнициФаза 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
Набиране на участнициФаза 1
- Fred Hutchinson Cancer Center, Seattle
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Набиране на участнициФаза 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Набиране на участнициФаза 1
- Swedish Cancer Institute, Seattle
Проучвания за Хронична лимфоцитна левкемия в други градове
- Boston, MA31 проучвания
- Columbus, OH28 проучвания
- Durham, NC27 проучвания
- Washington, DC22 проучвания
- Rochester, MN19 проучвания
- New York City, NY18 проучвания
- Houston, TX17 проучвания
- Baldwin Park, CA16 проучвания
- Milwaukee, WI15 проучвания
- Cincinnati, OH14 проучвания
- Chicago, IL14 проучвания
- Nashville, TN13 проучвания
Други проучвания в Seattle
- Рак на белия дроб с недребноклетъчен тип53 проучвания
- Рак (всички видове)49 проучвания
- Рак на простатата42 проучвания
- Остра миелоидна левкемия40 проучвания
- Рак на гърдата39 проучвания
- Метастатичен рак39 проучвания
- Колоректален рак34 проучвания
- Рак на белия дроб33 проучвания
- Рак на яйчниците30 проучвания
- Множествен миелом22 проучвания
- Миелодиспластични синдроми21 проучвания
- Остра лимфобластна левкемия21 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.